VIVUS has reported the glycemic findings from Equate, a phase-III trial evaluating Qnexain non-diabetic, obese patients.
After 28 weeks of treatment, blood sugar levels, as measured by hemoglobin A1c, were lower in the patients treated with Qnexa, while the patients in the placebo group had a significant increase in their HbA1c levels .
Leland Wilson, President and CEO of VIVUS, said: Data from DM-230 showed that treatment with Qnexa will lower HbA1c in diabetic patients, but we now know that for patients that have not been diagnosed with diabetes, Qnexa treatment can prevent increases in HbA1c levels.
“Obesity is the common cause of type 2 diabetes and other metabolic and cardiovascular diseases. In this study, treatment with Qnexa arrested progression to diabetes completely. These data highlight the important but often underappreciated potential of treating the major cause of diabetes before the disease becomes apparent, he added.